Ces radiol. 2019, 73(4):235-239 | DOI: 10.55095/CesRadiol2019/035

The benefit of measuring the size of incidentally detected adrenal lesions in the differential diagnosis of incidentalomasOriginal article

Filip Čtvrtlík1, Petr Kučera1, Paulína Szász1, Zuzana Sedláčková1, Kateřina Langová2, Igor Hartmann3, Jozef Škarda4, Jan Baxa5, Milan Hora6, Eva Kočová7, Jaroslav Pacovský8, Zbyněk Tüdös1
1 Radiologická klinika LF UP a FN, Olomouc
2 Ústav lékařské biofyziky LF UP, Olomouc
3 Urologická klinika LF UP a FN, Olomouc
4 Ustav klinické a molekulární patologie LF UP a FN, Olomouc
5 Klinika zobrazovacích metod LF UK a FN, Plzeň
6 Urologická klinika LF UK a FN, Plzeň
7 Radiologická klinika LF UK a FN, Hradec Králové
8 Urologická klinika LF UK a FN, Hradec Králové

Aim: The aim of the study was to evaluate the usefulness of the maximum size of a tumour examined with CT as a parameter for the differentiation of lipid-poor adenomas and primary adrenocortical carcinomas.

Methods: A multicentre retrospective study which was conducted at the University Hospital in Olomouc, Pilsen and Hradec Králové and included patients from the period 2003 to 2017 analyzes CT data from 2003 to 2017. It includes patients with adrenal tumours who underwent adrenalectomy followed by histological diagnosis. For this assessment, we selected only lipid-poor adenomas (with a native density above 10 HU) (96 cases) and primary adrenocortical carcinomas (32 cases). In total, 128 adrenal tumors were collected for the analysis. The maximum diameter and two perpendicular diameters were measured.

Results: The maximum size of the lesion is a significant indicator for distinguishing fat-poor adenomas from primary adrenocortical carcinomas. In the diagnosis of adenomas with a maximum tumor size limit of 5.05 cm, the sensitivity was 87.5% and the specificity was 90.6%.

Conclusion: Maximum expansion size is a suitable parameter for distinguishing lipid-poor adenomas and primary adrenocortical carcinomas.

Keywords: adenoma, adrenocortical carcinoma, computed tomography
Grants and funding:

Podpořeno z programového projektu Ministerstva zdravotnictví ČR s reg. č. 17-31847A.

Accepted: November 15, 2019; Published: December 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čtvrtlík F, Kučera P, Szász P, Sedláčková Z, Langová K, Hartmann I, et al.. The benefit of measuring the size of incidentally detected adrenal lesions in the differential diagnosis of incidentalomas. Ces radiol. 2019;73(4):235-239. doi: 10.55095/CesRadiol2019/035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. Am J Roentgenol 1996; 166(3): 531-536. Go to original source... Go to PubMed...
    2. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol 1998; 171(1): 201-204. Go to original source... Go to PubMed...
    3. Dunnick NR, Korobkin M. Imaging of Adrenal Incidentalomas: Current Status. Am J Roentgenol 2002; 179(3): 559-568. Go to original source... Go to PubMed...
    4. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005; 90(2): 871-877. Go to original source... Go to PubMed...
    5. Wale DJ, Wong KK, Viglianti BL, Rubello D, Gross MD. Contemporary imaging of incidentally discovered adrenal masses. Biomed Pharmacother 2017; 87: 256-262. Go to original source... Go to PubMed...
    6. Ghayee HK, Vinik AI, Pacak K, AACE Adrenal Scientific Committee. Precision medicine in adrenal disorders: the next generation. Endocr Pract 2017; 23(6): 672-679. Go to original source... Go to PubMed...
    7. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200(3): 743-747. Go to original source... Go to PubMed...
    8. Petersenn S, Richter P-A, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol 2015; 172(4): 415-422. Go to original source... Go to PubMed...
    9. Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol 2018; 178(5): 431-437. Go to original source... Go to PubMed...
    10. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175(2): G1-G34. Go to original source... Go to PubMed...
    11. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003; 138(5): 424-429. Go to original source... Go to PubMed...
    12. Libe R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147(4): 489-494. Go to original source... Go to PubMed...
    13. Čtvrtlík F, Koranda P, Tichý T. Adrenal disease: A clinical update and overview of imaging. A review. Biomedical Papers 2014; 158(1): 23-34. Go to original source... Go to PubMed...
    14. Mayo-Smith WW, Song JH, Boland GL, et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol 2017; 14(8): 1038-1044. Go to original source... Go to PubMed...
    15. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis. Eur Radiol 2018; 28(3): 1027-1036. Go to original source... Go to PubMed...
    16. Choi YA, Kim CK, Park BK, Kim B. Evaluation of adrenal metastases from renal cell carcinoma and hepatocellular carcinoma: use of delayed contrast-enhanced CT. Radiology 2013; 266(2): 514-520. Go to original source... Go to PubMed...
    17. Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of pheochromocytoma: Relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab 2019; 104(2): 312-318. Go to original source... Go to PubMed...
    18. Čtvrtlík F, Koranda P, Schovánek J, Škarda J, Hartmann I, Tüdös Z. Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy. Exp Ther Med 2018; 15(4): 3151-3160.
    19. Wein A, et al. Campbell-Walsh Urology, 11th Edition. Elsevier 2015.
    20. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234(2): 479-485. Go to original source... Go to PubMed...
    21. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85(2): 637-644. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content